HMG-COA reductase inhibitor extended release formulation

摘要

A controlled release oral solid dosage form for the reduction of serum cholesterol levels in humans comprising a drug that has an alkyl ester of hydroxy substituted napthalenes (for example lovastatin) and a controlled release carrier in an amount effective to provide a controlled release of the drug, the dosage form providing a mean time to maximum plasma concentration (TMAX) of the drug which occurs at about 10-32 hrs after oral administration.